Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul 1;117(13):2883-91.
doi: 10.1002/cncr.25900. Epub 2011 Jan 10.

Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer

Stephen A Boorjian  1 , R Jeffrey Karnes, Rosalia Viterbo, Laureano J Rangel, Eric J Bergstralh, Eric M Horwitz, Michael L Blute, Mark K Buyyounouski
Affiliations

Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer

Stephen A Boorjian et al. Cancer. .

Abstract

Background: The long-term survival of patients with high-risk prostate cancer was compared after radical prostatectomy (RRP) and after external beam radiation therapy (EBRT) with or without adjuvant androgen-deprivation therapy (ADT).

Methods: In total, 1238 patients underwent RRP, and 609 patients received with EBRT (344 received EBRT plus ADT, and 265 received EBRT alone) between 1988 and 2004 who had a pretreatment prostate-specific antigen (PSA) level ≥ 20 ng/mL, a biopsy Gleason score between 8 and 10, or clinical tumor classification ≥ T3. The median follow-up was 10.2 years, 6.0 years, and 7.2 years after RRP, EBRT plus ADT, and EBRT alone, respectively. The impact of treatment modality on systemic progression, cancer-specific survival, and overall survival was evaluated using multivariate Cox proportional hazard regression analysis and a competing risk-regression model.

Results: The 10-year cancer-specific survival rate was 92%, 92%, and 88% after RRP, EBRT plus ADT, and EBRT alone, respectively (P = .06). After adjustment for case mix, no significant differences in the risks of systemic progression (hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.51-1.18; P = .23) or prostate cancer death (HR, 1.14; 95% CI, 0.68-1.91; P = .61) were observed between patients who received EBRT plus ADT and patients who underwent RRP. The risk of all-cause mortality, however, was greater after EBRT plus ADT than after RRP (HR, 1.60; 95% CI, 1.25-2.05; P = .0002).

Conclusions: RRP alone and EBRT plus ADT provided similar long-term cancer control for patients with high-risk prostate cancer. The authors concluded that continued investigation into the differing impact of treatments on quality-of-life and noncancer mortality will be necessary to determine the optimal management approach for these patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Outcome for patients with high-risk prostate cancer treated with RRP, EBRT + ADT, or EBRT alone. (A) Systemic progression-free survival. (B) Cancer-specific survival (C) Overall survival.
Figure 2
Figure 2
Outcome for patients with high-risk prostate cancer treated with RRP, EBRT + ADT, or EBRT alone. Analysis restricted to radiation patients with a Charlson comorbidity index of 0–1. (A) Systemic progression-free survival. (B) Cancer-specific survival (C) Overall survival.
See this image and copyright information in PMC

Comment in

References

    1. Scardino P. Update: NCCN prostate cancer Clinical Practice Guidelines. J Natl Compr Canc Netw. 2005;3(suppl 1):S29–S33. - PubMed
    1. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE) J Urol. 2003;170:S21–S25. - PubMed
    1. Lawton CA, Winter K, Murray K, et al. Updated results of the phase III radiation therapy oncology group (RTOG) trial 85–31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;49:937–946. - PubMed
    1. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet. 2002;360:103–108. - PubMed
    1. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the radiation therapy oncology group protocol 92-02. J Clin Oncol. 2003;21:3972–3978. - PubMed

Publication types

MeSH terms